Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Trial Data
  5. Trial Initiation

Trial Initiation

Evaluate

February 21, 2023

Novo sows the seeds for a new heart failure approach

The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.

Thumbnail
February 10, 2023

Jemperli moves towards neoadjuvant rectal cancer at last

Article image
Vantage logo
February 10, 2023

The world needs Garp, according to Abbvie

After years of slow progress, and with very little supporting clinical data, Abbvie pledges to push into a major Garp inhibition programme.

Article image
Vantage logo
February 09, 2023

Astra tentatively takes Tigit pivotal

Bispecifics targeting Tigit and CTLA4 head into phase 3 development, as the developer follows Bristol out of IL-12.

Article image
Vantage logo
February 02, 2023

Kras opinions diverge

Article image
Vantage logo
February 01, 2023

Kras flatlines

Article image
Vantage logo
January 27, 2023

Anthos doubles down on its novel blood thinner

The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.

Article image
Vantage logo
November 18, 2022

Pulling back the curtain on Astrazeneca’s Car-T work

Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.

Article image
Vantage logo
November 02, 2022

If at first... pharma’s most drawn-out development timelines revealed

Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.

Article image
Vantage logo
August 05, 2022

Lilly goes head-to-head again, this time in obesity

Article image
Vantage logo
May 06, 2022

Anthos goes pivotal as Novartis and Pfizer look on

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up